BRSYF - Neuronetics Is Undervalued There Seems To Be A 40% Upside Potential
Neuronetics (STIM) recently released a solid quarterly report that included 30.94% revenue growth and a massive amount of cash. Almost 90% of its total amount of assets is represented by cash. The market did not seem to assess the figures reported and pushed the stock price down in November. At current prices, the company seems very undervalued as compared to peers. It trades at 3.2x forward sales, with other peers trading at 7.60x sales. With this in mind, there seems to be a 40% upside potential in the stock price.
Business
Founded in 2003 and